text: ENGLEWOOD, Colo., March 20, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), a leader in the development of Ampion™, a low molecular weight fraction of human serum albumin with anti-inflammatory properties, announced an update of corporate activities. As stated in a press release dated February 27, 2017, having recently concluded a successful series of meetings with the US Food and Drug Administration ("FDA"), Ampio is preparing to initiate what is anticipated to be the final pivotal trial of Ampion™ to treat the severe pain associated with Kellgren-Lawrence grade 4 osteoarthritis of the knee ("OAK"). As recommended by the FDA, the proposed primary endpoint for this study follows OARSI guidance, utilizing the OMERACT-OARSI responder rate. Using this responder rate definition, all previous Ampion™ single injections clinical trials would have successfully met this endpoint. In addition, Ampio plans to advance all necessary Biologic License Application (BLA) activities in parallel to expedite the path to potential FDA approval.
  Also, Ampio is pleased to announce that after an extensive process, the board of directors has selected Locust Walk to serve as a strategic advisor to the company. Locust Walk's charter will be to identify and evaluate potential strategic relationships for Ampion™. Among the many reasons, Locust Walk was selected due to their recent experience in securing transactions for similar stage therapeutics to treat pain as well as extensive knowledge of the OAK market. "I am very excited about Ampio's current position," said Michael Macaluso, Chairman, and CEO. "In the history of the company, we have never been as close to realizing what we believe to be the full potential of Ampion™, both from a regulatory perspective as well as commercial. I am thrilled to be working with Locust Walk to identify the optimal path to unlocking the value of Ampion™ for both patients and shareholders."
  To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-provides-corporate-update-300425890.html